about
Circulating microRNAs are new and sensitive biomarkers of myocardial infarctionAnthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.Circulating levels of dimethylarginines, chronic kidney disease and long-term clinical outcome in non-ST-elevation myocardial infarction.Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina.Vitamin D plasma levels and in-hospital and 1-year outcomes in acute coronary syndromes: a prospective studyB-type natriuretic peptide levels in patients with pericardial effusion undergoing pericardiocentesis.Brain natriuretic peptide in acute myocardial infarction: a marker of cardio-renal interaction.Myocardial Infarct Size in Patients on Long-Term Statin Therapy Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention.Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission.B-type natriuretic peptide and risk of acute kidney injury in patients hospitalized with acute coronary syndromes*.Reconstruction of the right atrium with pulmonary artery homograft after resection of right atrial lipomatosis.Impact of cardiac and renal dysfunction on inhospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty.Prognostic significance of serum creatinine and its change patterns in patients with acute coronary syndromesCavo-Atrial Metastases from Cutaneous MelanomaIncidence and Relevance of Acute Kidney Injury in Patients Hospitalized With Acute Coronary SyndromesContrast-induced nephropathy[Mild therapeutic hypothermia for the treatment of cardiac arrest and acute myocardial infarction]
P50
Q24606701-5B3218EC-FD15-4489-8C89-958BD59DA154Q33527690-CC9ACFB6-CA56-496C-8A7E-B0DFD8E06E9BQ34489684-D5E9F483-FE08-4DB2-A56F-CB4CBF0300CAQ35048954-25E7BE07-CC62-4C7D-85A1-3B3C6B0A9A4BQ36151577-32E0EA81-F65F-4654-A27D-C3AD99E44D51Q38884063-C96877D5-A47E-4ADD-858B-B49099DAB9A4Q38918910-E663E28F-4148-415A-BCF1-7241100DBA27Q38939236-E500F623-2CD1-43ED-BE02-B73B13923180Q42781472-020E314D-D0A0-4EFA-8FCB-F7BF8F7F50ACQ43269499-E104F603-5FE4-4129-8E8C-F926C5432F64Q43610719-BB7C42FC-C3B0-4CC6-8601-DDEA3DEB9819Q53464407-8F8398A9-A06A-4BBA-96CF-1CF577906784Q54250182-AB218180-5DF9-4284-B4C4-8E658C879120Q61387386-6CE0DAA0-627E-448D-A4C6-2443ED61E887Q61387391-14C7B957-96B3-4DDB-9DAE-FCF808BE06D5Q61387394-0AA0BF8A-535E-4F42-95C6-5CF05D2F6D6AQ61387403-423AF690-30C4-4ED2-A1C4-C820397BF887Q87435878-96160C5E-C1DE-41F8-91EB-08EFC4A17919
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mara Rubino
@ast
Mara Rubino
@en
Mara Rubino
@es
Mara Rubino
@nl
Mara Rubino
@sl
type
label
Mara Rubino
@ast
Mara Rubino
@en
Mara Rubino
@es
Mara Rubino
@nl
Mara Rubino
@sl
prefLabel
Mara Rubino
@ast
Mara Rubino
@en
Mara Rubino
@es
Mara Rubino
@nl
Mara Rubino
@sl
P1053
K-1537-2016
P106
P1153
7005030750
P21
P31
P3829
P496
0000-0001-7820-9814